Publication
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerHairy Cell Leukemiacivic_curation1.00
- drugVemurafenibcivic_curation1.00
- geneBRAFcivic_curation1.00
- geneKRAScivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantKRAS G12Dcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26352686
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E2 | ||||||||
| Vemurafenib | Hairy Cell Leukemia | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1579Two clinical trials evaluated the effects of vemurafenib in 54 patients with BRAF (V600E) positive hairy-cell leukemia. The overall response rate was 98% with 19/54 having a complete response and 34/… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC | civic |
| 〃 | Hairy Cell Leukemia | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID11315In these two phase II studies (Italy and U.S. locations), BRAF V600E-mutant hairy-cell leukemia was treated with vemurafenib at a dose of 960 mg twice daily to investigate its efficacy. The overall re… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC | civic |
| KRAS G12D1 | ||||||||
| Vemurafenib | Hairy Cell Leukemia | Predictive | C | Supports Resistance | 2 | accepted | EID1580One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC | civic |